home All News open_in_new Full Article

Biosidus Announces Promising Interim Results from Phase III Study on Agalsidase Beta for Fabry Disease

BUENOS AIRES, Argentina, April 16, 2025 (GLOBE NEWSWIRE) — Biosidus, an Argentinean pioneer company in biotechnology research, development, and the production of high-quality biosimilars, has announced encouraging interim results from the Phase III SMILE1 study. After 26 weeks of treatment, the study successfully met its primary endpoint, underscoring the potential of agalsidase beta as a […]


today 5 d. ago attach_file Other

attach_file Culture
attach_file Politics
attach_file Economics
attach_file Sport
attach_file Economics
attach_file Culture
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Events
attach_file Economics
attach_file Other
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Other
attach_file Other
attach_file Sport


ID: 2185702215
Add Watch Country

arrow_drop_down